Clinical trials have shown that the new vaginal device safely delivers at least 10-times more drug to the uterus as a tablet of equivalent dose.
During the study, the researchers recruited 18 participants, aged 18-45 years with menstrual cycles between 25-30 days.
In the mid-follicular phase of the first menstrual cycle (days 7-11), nine study participants received an oral dose of 10 mg of ketorolac (Toradol), a non-steroidal anti-inflammatory medication; while nine women received a tampon coated with 10 mg of ketorolac.
During the second menstrual cycle, each subject received the opposite treatment.
The results revealed that the medication administered vaginally does not cause significant side effects but accumulates more efficiently in the desired uterine tissue than using the oral medication.
"While still early in our research, this study shows promising results which may help pave the way for new treatment options for women," said Dr Giovanni M. Pauletti, associate professor at the University of Cincinnati.
"Phase II clinical trials will study efficacy of the treatment to assess whether the drug concentration is effective in reducing pain," Pauletti added.
The study was presented at American Association of Pharmaceutical Scientists (AAPS) Annual Meeting and Exposition.